Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1823196 | 0.98 | RAB9A (0.43) | RAB9ANPC1MEN1MAPK1KMT2A | |
| SCHEMBL13232308 | 0.78 | TDP1 (0.54) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL111257 | 0.78 | CA12 (0.54) | RAB9ANPC1MEN1MAPK1KMT2A | |
| SCHEMBL12209960 | 0.77 | SMN1; SMN2 (0.41) | RAB9ANPC1MEN1MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL561736 | 0.76 | CA12 (0.52) | RAB9ANPC1MEN1MAPK1KMT2A | |
| SCHEMBL9603059 | 0.76 | MAPT (0.45) | RAB9ANPC1MEN1MAPK1KMT2A | |
| SCHEMBL6973449 | 0.76 | LMNA (0.48) | RAB9ANPC1MEN1MAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL11615422 | 0.76 | TDP1 (0.52) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL18773359 | 0.76 | PLAU (0.52) | MEN1MAPK1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12669446 | 0.76 | PRSS1 (0.61) | RAB9ANPC1MAPK1MAPTCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | RAB9A 2351/4885NPC1 818/4885MEN1 3036/4885 |
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | RAB9A 1528/4885NPC1 585/4885MEN1 666/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | RAB9A 2351/4885NPC1 818/4885MEN1 3036/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | RAB9A 977/4885NPC1 825/4885MEN1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.